insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

INDP · Indaptus Therapeutics, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · INDP

1Y3Y5YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$491.1K-$1.52M$2.17M$2.81M-$1.47M$1.71M$1.59M-
SG&A$1.67M-$1.13M$2.29M$1.76M-$1.68M$2.39M$2.35M-
Total Operating Expenses$2.16M-$2.65M$4.46M$4.57M-$3.14M$4.11M$3.94M-
D&A--------$735-
Operating Income($2.16M)-($2.65M)($4.46M)($4.57M)-($3.14M)($4.11M)($3.94M)-
Interest Expense----------
Income Tax----------
Net Income($2.54M)-($2.98M)($5.23M)($4.53M)-($3.07M)($4.02M)($3.81M)-
EPS - Basic($0.23)-($2.98)($9.09)($8.96)-($8.96)($13.16)($12.60)-
EPS - Diluted($0.23)-($2.98)($9.09)($8.96)-($8.96)($13.16)($12.60)-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$1.50M$8.51M$5.83M$6.16M$3.89M$5.79M$7.38M$7.30M$9.74M$13.36M
Accounts Receivable----------
Inventory----------
Accounts Payable$557.4K$544.1K$707.4K$618.5K$1.31M$870.2K$555.9K$416.6K$405.5K$806.0K
Current Assets$2.18M$9.31M$6.44M$6.41M$4.96M$6.62M$7.63M$7.49M$10.29M$14.00M
Total Assets-$9.31M$6.84M$6.84M$5.41M$7.34M$8.24M$8.12M$10.95M$14.92M
Current Liabilities$933.0K$6.16M$2.23M$8.51M$2.61M$3.39M$2.23M$1.93M$1.54M$2.77M
Long-term Debt----------
Total Liabilities-----$3.39M$2.24M$1.96M$1.59M$2.85M
Stockholders' Equity$1.25M$3.15M$4.61M($1.67M)$2.80M$3.94M$6.00M$6.17M$9.36M$12.08M
Retained Earnings($83.83M)($81.29M)($73.18M)($70.20M)($64.97M)($60.44M)($56.31M)($53.24M)($49.22M)($45.42M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($7.01M)---($5.05M)---($3.94M)-
Investing Cash Flow----------
Financing Cash Flow----$3.15M---$316.0K-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets---43.5%-76.5%-83.8%--37.2%-49.4%-34.8%-
Return on equity-203.6%--64.6%312.5%-161.9%--51.1%-65.1%-40.7%-
Return on invested capital----------
Liquidity
Current ratio2.341.512.880.751.901.953.423.886.705.05
Quick ratio2.341.512.880.751.901.953.423.886.705.05
Cash ratio1.611.382.610.721.491.713.313.796.344.82
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier-2.951.49-4.091.931.861.371.321.171.24
Liabilities / Assets-----0.460.270.240.150.19
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B16.0x-0.6x-77.6x-55.0x82.2x56.6x-
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)52.8%-15.7%-8.5%-16.0%-26.0%-17.6%11.5%-
Net income growth (YoY)43.9%-3.1%-30.2%-19.1%-21.8%-23.7%10.5%-
EPS growth (YoY)97.4%-66.7%30.9%28.9%--1806.4%-2760.9%--
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)-55.4%-20.1%-23.3%--70.1%-67.3%-60.8%-66.9%-55.8%-51.0%

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing Indaptus Therapeutics against the 5 most active filers in the same SIC group.